- The Company can develop and market technological know-how in the area of bio-printing for itself and third parties, perform itself or arrange for third parties to perform the necessary research and development work as well as the production, distribution and service work, acquire, use, administrate and sell real estate and intellectual property rights as well as establish subsidiaries and branch offices. The Company may enter into all business transactions and conclude contracts which are suited to promote the purpose of the Company or which are directly or indirectly associated therewith, such as the marketing of its own and foreign technological know-how with regard to the 3D screen printing technology by means of industrial property rights by granting and taking licences and the purchase or disposal of industrial property rights.
- Numerous highly innovative projects are in the development phase, among them 3D bio-printing skin models, cell tissue, microarrays and organoids.
- Founded in Nov. 2018. - Axenoll® owns the worldwide licence right for cellular and molecular 3D bio-printing within the framework of clean room research & development, production and marketing on the basis of the patented Exentis 3D Mass Customization® and the Exentis 3D screen printing technology. – In its capacity as technology company, Axenoll® develops and industrializes projects, starting with the development project and up to the million-fold production.
